作者：Qin Tian, Zhi Yuan, et al
關鍵字：Glycyrrhetinic acid,Chitosan,Poly(ethylene glycol),Liver-targeting
論文來源：期刊
發表時間：2010年
A liver-targeted drug delivery carrier, composed of chitosan/poly(ethylene glycol)eglycyrrhetinic acid (CTS/PEGeGA) nanoparticles, was prepared by an ionic gelation process, in which glycyrrhetinic acid (GA) acted as the targeting ligand. The formation and characterization of these nanoparticles were confirmed by FT-IR, dynamic light scattering (DLS) and zeta potential measurements. The biodistribution of the nanoparticles was assessed by single-photon emission computed tomography (SPECT), and the cellular uptake was evaluated using human hepatic carcinoma cells (QGY-7703 cells). The anti-neoplastic
effect of the doxorubicin$HCl-loaded nanoparticles (DOX-loaded nanoparticles) was also investigated in vitro and in vivo. The results showed that the CTS/PEGeGA nanoparticles were remarkably targeted to the liver, and keep at a high level during the experiment. The accumulation in the liver was 51.3% at 3 h after injection; this was nearly 2.6 times that obtained with the CTS/PEG nanoparticles. The DOX-loaded nanoparticles were greatly cytotoxic to QGY-7703 cells, and the IC50 (50% inhibitory concentration) for the free doxorubicin$HCl (DOX$HCl) and the DOX-loaded CTS/PEGeGA nanoparticles were 47 and 79 ng/mL, respectively. Moreover, the DOX-loaded CTS/PEGeGA nanoparticles could effectively inhibit tumor
growth in H22 cell-bearing mice.